Reações adversas aos anticorpos monoclonais para doenças alérgicas
Adverse reactions to monoclonal antibodies in allergic diseases
Sérgio Duarte Dortas-Junior; Aldo José Fernandes Costa; Marta de Fátima Rodrigues da Cunha Guidacci; Filipe W. Sarinho; Faradiba Sarquis Serpa; Eduardo Costa Silva; João Negreiros Tebyriça; Nelson Augusto Rosario-Filho; Norma de Paula M. Rubini; Régis de Albuquerque Campos
Resumo
A utilização de agentes imunobiológicos em alergia e imunologia tem sido cada vez mais frequente nos últimos anos, emergindo como potencialmente eficazes para o tratamento de doenças alérgicas e de hipersensibilidade. O uso de imunobiológicos em doenças alérgicas está recomendado nas formas graves onde a eficácia, segurança e custo-efetividade estão comprovados. O objetivo deste artigo é sintetizar os efeitos adversos mais comuns ou significativos, incluindo as reações de hipersensibilidade aos principais anticorpos monoclonais aprovados para o tratamento de doenças alérgicas licenciados e comercializados no Brasil até o momento.
Palavras-chave
Abstract
The use of immunobiological agents in allergy and immunology has increased in recent years, emerging as potentially effective strategies to treat allergic and hypersensitivity diseases. The use of immunobiological agents is recommended in the severe forms of allergic diseases, for which their efficacy, safety, and cost-effectiveness have been established. The purpose of this study was to summarize the most common or significant adverse effects, including hypersensitivity reactions to the main monoclonal antibodies approved for the treatment of allergic diseases that are currently licensed and marketed in Brazil.
Keywords
Referências
1. Solé D, Sano F, Rosário NA, Antilla M, Aranda C, Chong-Neto H et al. Guia prático de atualização: medicamentos biológicos no tratamento da asma, doenças alérgicas e imunodeficiências. Arq Asma Alergia Imunol. 2019;3:207-49.
2. Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110-116.e7.
3. Wandalsen GF, Sano F, Falcão ACAM, Machado AS, Serpa FS, Rizzo JÂ, et al. Guia para o manejo da asma grave 2019 – Associação Brasileira de Alergia e Imunologia. Arq Asma Alerg Imunol. 2019;3(4):337-62.
4. Abuzakouk M, Ghorab OKHA, Wahla AS, Zoumot Z, Nasir M, Grandon D, et al. Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis - A Real-life Experience. Open Respir Med J. 2020 Dec 31;14:99-106.
5. Giavina-Bianchi P, Arruda LK, Aun MV, Campos RA, Chong-Neto HJ, Constantino-Silva RN, et al. Diretrizes brasileiras para o diagnóstico e tratamento do angioedema hereditário - 2017. Arq Asma Alerg Imunol. 2017;1(1):23-48.
6. Aubin F, Carbonnel F, Wending D. The complexity of adverse sideeffects to biological agents. J Crohns Colitis. 2013;7:257-62.
7. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006 Aug;61(8):912-20.
8. bula Xolair® (Internet). Disponível em: https://portal.novartis.com.br/upload/imgconteudos/2130.pdf.
9. Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother. 2007 Sep;41(9):1397‑410.
10. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009 Jun;39(6):788‑97.
11. Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012 Apr;129(4):983-9. e6.
12. Barakat L, Torres MJ, Phillips EJ, Caminati M, Chang YS, Caimmi D, et al. Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1396-1399.e2.
13. Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol. 2010 Dec;105(6):493-5.
14. Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf. 2011;6(5):339-42.
15. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007 May-Jun;28(3):313-9.
16. Baker DL, Nakamura GR, Lowman HB, Fischer SK. Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis. AAPS J. 2016 Jan;18(1):115-23.
17. Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26:551-6.
18. Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173(2):404-15.
19. Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. JAMA Dermatol. 2019 Jan 1;155(1):29-38.
20. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020 Sep;146(3):595-605.
21. Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1379-92.
22. bula Nucala® (Internet). Disponível em: https://br.gsk.com/media/6289/l1307_nucala_po_lio_inj_gds11.pdf .
23. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term Efficacy and Safety of Mepolizumab in Patients with Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016 Sep;38(9):2058-2070.e1.
24. Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7.
25. Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021 Jun 3;11(4):e12038.
26. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023-42.
27. Logan J, Harinstein L. Pediatric postmarketing pharmacovigilance review of mepolizumab: Food and Drug Administration; 2017.
28. Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma. Expert Rev Clin Immunol. 2017 May;13(5):405-13.
29. bula Fasenra® (Internet). Disponível em: https://www.astrazeneca.com.br/content/dam/az-br/Medicine/InfoFasenra/Fasenra_Bula_Profissional%20-%20FSN003.pdf
30. Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020 Mar;16(3):311-9.
31. Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 Jan;7(1):46-59.
32. Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018 Jul;18(7):747-54.
33. b u l a D u p i x e n t ® ( I n t e r n e t ) . D i s p o n í v e l e m : http://200.199.142.163:8002/FOTOS_TRATADAS_SITE_14-03-2016/bulas/75769.pdf
34. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-96.
35. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475-85.
36. Bacharier LB, Maspero JF, Katelaris CH, Fiocchi, AG, Gagnon R, de Mir I, et al. Dupilumab in Children with Uncontrolled Moderateto-Severe Asthma. N Engl J Med. 2021;385:2230-40.
37. Utine CA, Li G, Asbell P, Pflugfelder S, Akpek E. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021 Jan;19:151-6.
38. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/ S0140-6736(19)31881-1. Epub 2019 Sep 19. Erratum in: Lancet. 2019 Nov 2;394(10209):1618.
39. Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol. 2022 Mar;86(3):708-9.
Submetido em:
26/04/2022
Aceito em:
18/06/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email